These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. Cingolani HE; Plastino JA; Escudero EM; Mangal B; Brown J; Pérez NG J Card Fail; 2006 Sep; 12(7):491-8. PubMed ID: 16952781 [TBL] [Abstract][Full Text] [Related]
4. Preservation of cardiac contractility after long-term therapy with oxypurinol in post-ischemic heart failure in mice. Tan Z; Dai T; Zhong X; Tian Y; Leppo MK; Gao WD Eur J Pharmacol; 2009 Oct; 621(1-3):71-7. PubMed ID: 19737552 [TBL] [Abstract][Full Text] [Related]
5. Allopurinol or oxypurinol in heart failure therapy - a promising new development or end of story? Reyes AJ; Leary WP Cardiovasc Drugs Ther; 2005 Oct; 19(5):311-3. PubMed ID: 16382292 [TBL] [Abstract][Full Text] [Related]
6. The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy. Springer J; Tschirner A; Hartman K; von Haehling S; Anker SD; Doehner W Int J Cardiol; 2013 Oct; 168(4):3527-31. PubMed ID: 23751350 [TBL] [Abstract][Full Text] [Related]
9. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Minhas KM; Saraiva RM; Schuleri KH; Lehrke S; Zheng M; Saliaris AP; Berry CE; Barouch LA; Vandegaer KM; Li D; Hare JM Circ Res; 2006 Feb; 98(2):271-9. PubMed ID: 16357304 [TBL] [Abstract][Full Text] [Related]
10. Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Kögler H; Fraser H; McCune S; Altschuld R; Marbán E Cardiovasc Res; 2003 Sep; 59(3):582-92. PubMed ID: 14499859 [TBL] [Abstract][Full Text] [Related]
11. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. Hare JM; Mangal B; Brown J; Fisher C; Freudenberger R; Colucci WS; Mann DL; Liu P; Givertz MM; Schwarz RP; J Am Coll Cardiol; 2008 Jun; 51(24):2301-9. PubMed ID: 18549913 [TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome. McGaurn SP; Davis LE; Krawczeniuk MM; Murphy JD; Jacobs ML; Norwood WI; Clancy RR Pediatrics; 1994 Dec; 94(6 Pt 1):820-3. PubMed ID: 7970996 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates. Chu WY; Annink KV; Nijstad AL; Maiwald CA; Schroth M; Bakkali LE; van Bel F; Benders MJNL; van Weissenbruch MM; Hagen A; Franz AR; Dorlo TPC; Allegaert K; Huitema ADR; Clin Pharmacokinet; 2022 Feb; 61(2):321-333. PubMed ID: 34617261 [TBL] [Abstract][Full Text] [Related]
15. Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Spector T Biochem Pharmacol; 1988 Jan; 37(2):349-52. PubMed ID: 2829916 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of xanthine oxidase by 4-hydroxy-6-mercaptopyrazolo[3,4-d]pyrimidine. Spector T; Hall WW; Porter DJ; Lambe CU; Nelson DJ; Krenitsky TA Biochem Pharmacol; 1989 Dec; 38(23):4315-20. PubMed ID: 2557043 [TBL] [Abstract][Full Text] [Related]
17. Role of xanthine oxidoreductase in the reversal of diastolic heart failure by candesartan in the salt-sensitive hypertensive rat. Yamamoto E; Kataoka K; Yamashita T; Tokutomi Y; Dong YF; Matsuba S; Ogawa H; Kim-Mitsuyama S Hypertension; 2007 Oct; 50(4):657-62. PubMed ID: 17709654 [TBL] [Abstract][Full Text] [Related]
18. Role of NADPH oxidase and xanthine oxidase in mediating inducible VT/VF and triggered activity in a canine model of myocardial ischemia. Martins JB; Chaudhary AK; Jiang S; Kwofie M; Mackie P; Miller FJ Int J Mol Sci; 2014 Nov; 15(11):20079-100. PubMed ID: 25375191 [TBL] [Abstract][Full Text] [Related]
19. Biochemical and mechanical dysfunction in a mouse model of desmin-related myopathy. Maloyan A; Osinska H; Lammerding J; Lee RT; Cingolani OH; Kass DA; Lorenz JN; Robbins J Circ Res; 2009 Apr; 104(8):1021-8. PubMed ID: 19299643 [TBL] [Abstract][Full Text] [Related]
20. Physiologic levels of uric acid inhibit xanthine oxidase in human plasma. Tan S; Radi R; Gaudier F; Evans RA; Rivera A; Kirk KA; Parks DA Pediatr Res; 1993 Sep; 34(3):303-7. PubMed ID: 8134172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]